Abstract 848P
Background
This observational real-world study used propensity score matching (PSM) to compare tumor lysis syndrome (TLS) associated mortality in patients (pts) with hematological malignancies who received either rasburicase or allopurinol monotherapy. Goldman/Cairo previously published that rasburicase significantly, more rapidly reduces uric acid exposure (AUC) compared to allopurinol in pts with/at risk of TLS.
Methods
In 2021, 266 oncologists provided anonymized data for 715 liquid tumor pts treated in past year for hyperuricemia (HU) risk and TLS potential. Out of 715, 282 rasburicase and allopurinol pts without spontaneous TLS or TLS before HU treatment (Tx) were matched using 11 pre-HU Tx covariates: acute renal failure, age, anti-cancer Tx, creatinine, gender, LDH, perceived risk, renal disease, tumor type, uric acid, and white blood cells. Matched pts met 1:1, nearest neighbor, caliper matching requirements (width=0.2) of standard deviation of logit of the PSM (d score) on covariates, regardless of whether pts later developed TLS post-HU Tx. Assessments include mean uric acid (UA) levels, anti-cancer Tx, and, as feasible, timing of death relative to HU Tx.
Results
The PSM was almost 0.6 before and near 0 after matching; no covariate had a large imbalance (│d│>0.25) before and after. Of 141 pts in each pt group, TLS-associated mortality was significantly less likely among rasburicase pts (2.1% [n = 3] vs. 7.1% [n = 10], P = 0.047) (71% reduction). Of 63 pt subset who developed TLS after HU Tx, TLS-associated fatalities were even less likely among rasburicase vs. allopurinol pts (8.3% [n = 3] vs. 37% [n = 10], P = 0.005). Comparing 13 who died vs. 269 who lived, no significant difference in mean UA was found (13.5 mg/dL vs. 11.4, respectively). Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) was the predominant Tx among those who did not die (15%, n = 41). Only 1/13 pts died of R-CHOP. Seven pts died within 2 weeks of allopurinol (n = 6) or rasburicase (n = 1) monotherapy (timing not established for other 6).
Conclusions
PSM corrects before and after overall covariate and individual baseline covariate imbalances and rasburicase compared with allopurinol significantly reducing TLS-associated mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sanofi.
Disclosure
J.R. Gallagher, S. Carroll: Financial Interests, Full or part-time Employment: Clarity Pharma. E.J. Drea, Y.J. Barnes, C. Clark: Financial Interests, Stocks/Shares: Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18